Cubist Systematic Strategies’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Cubist Systematic Strategies’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-395	Closed	-$8.35K	–	4116
2023 Q2	$8.35K	Buy	+395	New	+$12.2K	﹤0.01%	3276
2022 Q3	–	Sell	-800	Closed	-$151K	–	4860
2022 Q2	$151K	Sell	800 -822	-51%	-$166K	﹤0.01%	3817
2022 Q1	$404K	Buy	1,622 +1,342	+479%	+$212K	﹤0.01%	2666
2021 Q4	$44K	Buy	+280	New	+$54.1K	﹤0.01%	3321
2020 Q2	–	Sell	-582	Closed	-$119K	–	2561
2020 Q1	$119K	Buy	+582	New	+$186K	﹤0.01%	1865
2019 Q3	–	Sell	-563	Closed	-$179K	–	2554
2019 Q2	$179K	Buy	+563	New	+$195K	﹤0.01%	2090
2015 Q2	–	Sell	-46	Closed	-$389K	–	2088
2015 Q1	$389K	Buy	46 +41	+820%	+$358K	0.02%	1095
2014 Q4	$40K	Buy	+5	New	+$29K	﹤0.01%	1791

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's EIGR Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 395 shares — an estimated $8.35K sold.

Cubist Systematic Strategies first reported a position in EIGR in Q4 2014 and held it in 8 quarters. The position peaked at $404K in Q1 2022. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

Cubist Systematic Strategies reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 395 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $8.35K.
Cubist Systematic Strategies first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2014 and held it in 8 quarters.
Cubist Systematic Strategies's Eiger BioPharmaceuticals, Inc. position peaked at $404K in Q1 2022.
51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.